A vaccine against streptococcus pyogenes: The potential to prevent rheumatic fever and rheumatic heart disease

American Journal of Cardiovascular Drugs

Volumn 13, Issue 1, 2013, Pages 1-4

  Guilherme, Luiza ^a,b   Ferreira, Frederico Moraes ^a,b   Köhler, Karen Francine ^a,b   Postol, Edilberto ^a,b   Kalil, Jorge ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL INSTITUTE OF SCIENCE AND TECHNOLOGY   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; STREPTINCOR VACCINE; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ARTICLE; CHEMICAL STRUCTURE; CIRCULAR DICHROISM; CROSS REACTION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SAFETY; DRUG STRUCTURE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PH; PRIORITY JOURNAL; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; STREPTOCOCCUS PYOGENES; TRANSGENIC MOUSE;

ANIMALS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA ANTIGENS; HUMANS; RHEUMATIC FEVER; RHEUMATIC HEART DISEASE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; VACCINATION;

EID: 84874064090     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-013-0005-8     Document Type: Article

References (16)

1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5(11):685-94.
2. Barbosa PJB, Müller RE, Latado AL, Achutti AC, Ramos AIO, Weksler C, et al. (2009) Diretrizes Brasileiras para Diagnóstico, Tratamento e Prevenção da Febre Reumática da Sociedade Brasileira de Cardiologia, da Sociedade Brasileira de Pediatria e da Sociedade Brasileira de Reumatologia (Brazilian guidelines for the diagnosis, treatment and prevention of rheumatic fever). Arq Bras Cardiol. 93(3 Suppl 4):1-18.
3. Fischetti VA, Windels M. Mapping the immunodeterminants of the complete streptococcal M6 protein molecule. Identification of an immunodominant region. J Immunol. 1988;141(10):3592-9.
4. Olive C, Clair T, Yarwood P, Good MF. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Vaccine. 2002;20(21-22):2816-25.
5. Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, Wasserman SS, Dale JB. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA. 2004;292(6):709-15.
6. Robinson JH, Atherton MC, Goodacre JA, Pinkney M, Weightman H, Kehoe MA. Mapping T-cell epitopes in group A streptococcal type 5 M protein. Infect Immun. 1991;59(12):4324-31.
7. Batzloff M, Yan H, Davies M, Hartas J, Good M. Preclinical evaluation of a vaccine based on conserved region of M protein that prevents group A streptococcal infection. Indian J Med Res. 2004;119(Suppl):104-7.
8. McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, Baxendale DM, Reddish MA, Hu MC, Stroop SD, Linden J, Fries LF, Vink PE, Dale JB. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis. 2005;41(8):1114-22.
9. Guilherme L, Faé KC, Higa F, Chaves L, Oshiro SE, Freschi de Barros S, Puschel C, Juliano MA, Tanaka AC, Spina G, Kalil J. Towards a vaccine against rheumatic fever. Clin Dev Immunol. 2006;13(2-4):125-32.
10. Guilherme L, Postol E, Freschi de Barros S, Higa F, Alencar R, Lastre M, Zayas C, Puschel CR, Silva WR, Sa-Rocha LC, Sa-Rocha VM, Pérez O, Kalil J. A vaccine against S. pyogenes: design and experimental immune response. Methods. 2009;49(4):316-21.
11. Pandey M, Batzloff MR, Good MF. Mechanism of protection induced by group A Streptococcus vaccine candidate J8-DT: contribution of B and T-cells towards protection. PLoS One. 2009;4(4):e5147.
12. Steer AC, Batzloff MR, Mulholland K, Carapetis JR. Group A streptococcal vaccines: facts versus fantasy. Curr Opin Infect Dis. 2009;22(6):544-52.
13. Guilherme L, Alba MP, Ferreira FM, Oshiro SE, Higa F, Patarroyo ME, Kalil J. Anti-group A streptococcal vaccine epitope: structure, stability, and its ability to interact with HLA class II molecules. J Biol Chem. 2011;286(9):6989-98.
14. Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR. Thermal stability of vaccines. J Pharm Sci. 2003;92(2):218-31.
15. Acevedo R, Callicó A, del Campo J, González E, Cedré B, González L, Romeu B, Zayas C, Lastre M, Fernández S, Oliva R, García L, Pérez JL, Pérez O. Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice. Methods. 2009;49:309-15.
16. Guerino MT, Postol E, Demarchi LM, Martins CO, Mundel LR, Kalil J, Guilherme L. HLA class II transgenic mice develop a safe and long lasting immune response against StreptInCor, an anti-group A streptococcus vaccine candidate. Vaccine. 2011;29(46):8250-6.